He is actually correct, large amount by the same buyer all afternoon, either covering or accumulating. Either one I keeping the price above .34
since the reverse split over a year ago. It is safe to say the share price will continue like that for another year. This month guarantees an increase of at least 7% from $1.70, which can either add to it from there or rest back where it began.
Noticed that right after #1 you mentioned Zohydro, which the new version was approved a year ago. It sales had the breaks on due to the required exchange from the old version to the new Zohydro Beadtek. I do agree they got a bad deal when acquiring the drug. Since Zogenix couldn't wait to get rid of the headache they received from the government since first approved, not only did they over paid for the drug, but they also took Zohydro's oversized sales department getting ahead of themselves. Hopefully that will play in their favor, now that its largest competitor is getting investigated and Zohydro Beadtek does not produce toxicity on the liver.
I also noticed you don't mention Silenor in that list, which Pernix just finished a comparison study with Zolpiden showing its advantages and will definitely help overall sales.
might be so, but at the same time Ziopharm realized that they don't want to be tie down so much and are willing to pay a monthly dividend of 1% payable in additional preferred shares, in addition to the $120 M. I guess they are expecting the product to be worth a lot more.
gave them more than two million shares in exchange to reduce operating profit rates payable to Intrexon from ZIOP on products developed under its two existing collaborations from 50% to 20%.
Stop sounding so ignorant for some one who has been trading that whole time. You cannot compare traders with investors, for if it wasn’t for them, there would not be a market to trade in. Investors who have sold their positions in Oncosec took their money elsewhere to invest in a company that they can trust, and used their lost for tax deductions. Some of those sellers might still have Oncosec on the radar and will come back, however, the investors that stayed or opened a position after the Nasdaq listing, decided to trust their research. They strongly believe that eventually a sell for a profit is possible, regardless of the time needed or attainable money in comparison to your expectations. Sometimes it ends up working out better for traders, but most of the times it works out better for investors, if proper research is done. It really all comes down to the individuals timing, the amount of risk they are willing to put on, and the type of liquidity needed.
At this point in time, it is a good idea to consider Oncosec for their near term goals which will help define the company’s future. It is the same thesis as for every other company that takes part in any of the higher exchanges, who are all working towards building a future.
They pump as you eloquently put it because there is money to be made with Oncosec, whether it be by trading or holding. Just look at my previous message from last week and see where the price is today. You missed out on a profit taking that is available because you are too busy thinking that you are always correct. Well it seems times are changing, and you either get with the program or continue looking like a fool. You spend enough time on this board, around 3 years waiting for it to drop? and you continue to criticize share holders. If it wasn't for them, there would not be a company for you to leech upon.
"this technology will minimize collateral cell death and reduce treatment variability observed in patients. These findings represent a significant advancement in gene electro-transfer, because retaining the viability of transfected cells is critical for treatment success." Sounds better than a simple may.
OOPS, you wrote that early in trading day and the price only dropped 2% by the end of it, creating a nice long legged doji, guess who is going to be wrong today. I hope you listened and took advantage of it. You want me to say something with more substance, however, it is OncoSec that is presenting ‘Significant Advancements in Electroporation Technology for Immunotherapy’.
thanks, on that note, let me share some new information about Interleukin-12. The title of the article is 'Legions Of Immune Cells In The Lung Keep Legionella At Bay', in which a major response that can control the disease has been found.
According to the study " monocyte-derived cells are part of the immune system’s first line of defense against the bacteria, and in this case, responded to the infection by secreting a chemical messenger called interleukin-12. This, in turn, drove immune T cells to produce large amounts of interferon gamma, another powerful chemical messenger of the immune system that instructed the MCs to kill the engulfed Legionella bacteria."
This is exactly the same response that IL-12 is producing in melanoma and will benefit when combined with anti PD-L1.
The abstract was published on June 14, with the tittle: Cooperation between Monocyte-Derived Cells and Lymphoid Cells in the Acute Response to a Bacterial Lung Pathogen.
In a day like today, it is one of the few companies trading today positive. It is obvious Oncosec is getting ready to surge new highs with the help of good news in the horizon. At the present price of recent offering, I think why not? Over $2 before next Christmas!
OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy.
"We are delighted that our collaborators are presenting data at ASCO demonstrating the utility of the flow cytometric TIL assay," said Robert H. Pierce, MD, Chief Scientific Officer at OncoSec. "Our ongoing investigator-sponsored combination trial of ImmunoPulse™ IL-12 and pembrolizumab hinges on the strong predictive value for poor treatment outcomes from this assay. Given these data, we are confident that we will be able to robustly identify a combination efficacy signal in our ongoing single-arm trial."
It is never too late to change and make a difference in life. The way you express yourself is the same way you see yourself. Your actions and words are the mirror of your soul.
It is too much for him to face his own self-hate, so he ends projecting his own issues onto others. It is not only that his put-downs always reflect what he does not like about himself, but his put-downs also allows him to keep his own toxic shame at bay.
The track record for liking the science of Oncosec has always been positive, just like my bank account. There are many ways to be profitable in the market, just as many to loose money. I focus in not loosing, that's my secret.
Keeping up with abstracts is probably more important than researching companies’ financials, when it comes to bios. It is the method I use when choosing to follow a company and the best way to be ahead of other investors found in conferences. ASCO is a platform for science to pave the road for investors who have access to the money that follows. Even though Oncosec is not attending the 2016 ASCO, one can see how its value increased after interim results for melanoma in December 2013 were presented at the Advances in Cancer Immunotherapy conference. The impression left by the data presented gave Oncosec the highest market cap it has ever had heading towards ASCO 2014. Analysts presently continue to use that increase as a price target.
In an abstract just released from Array BioPharma, a Phase 2 study of 102 patients were randomized to receive the doublet regimen of encorafenib and cetuximab or the triplet regimen of encorafenib, cetuximab and alpelisib . The Median OS was 12.4 and 13.1 months for the doublet and triplet regimens, respectively. Median progression-free survival was 4.2 and 5.4 months for the doublet and triplet regimens, respectively. Overall response rate was 22% for the doublet and 27% for the triplet regimens. Array owns both encorafenib and cetuximab, and if comparing those results with what Oncosec released on their Phase 2 melanoma presentation back in 2014, I can only imagine the data to be presented in their next abstract of the combination study with Keytruda for patients to who anti PD-1 alone did not help.
only to show why it is important to learn about abstracts. It makes it easier to make money. Learn.